(Hetero)aryl cyclopropylamine compounds as LSD1 inhibitors
AssigneeOryzon Genomics, S.A.
InventorsAlberto Ortega Muñoz, Matthew Colin Thor Fyfe, Marc Martinell Pedemonte, Maria de los Àngeles Estiarte Martinez, Nuria Valls Vidal, Guido Kurz, Julio Cesar Castro Palomino Laria
Life of this patent
Estimating the term…
Abstract
The invention relates to (hetero)aryl cyclopropylamine compounds, including particularly the compounds of formula I as described and defined herein, and their use in therapy, including, e.g., in the treatment or prevention of cancer, a neurological disease or condition, or a viral infection.
Claims19
A compound selected from
- N-((trans)-2-(2-fluorophenyl)cyclopropyl)piperidin-4-amine;
- and
- N-((trans)-2-(o-tolyl)cyclopropyl)piperidin-4-amine;
- or a salt thereof.
A pharmaceutical composition comprising a compound selected from
- N-((trans)-2-(2-fluorophenyl)cyclopropyl)piperidin-4-amine;
- and
- N-((trans)-2-(o-tolyl)cyclopropyl)piperidin-4-amine;
- or a pharmaceutically acceptable salt thereof,
- and a pharmaceutically acceptable carrier.
A method of treating cancer, the method comprising administering, to a subject in need of such treatment, a compound selected from
- N-((trans)-2-(2-fluorophenyl)cyclopropyl)piperidin-4-amine;
- and
- N-((trans)-2-(o-tolyl)cyclopropyl)piperidin-4-amine;
- or a pharmaceutically acceptable salt thereof.
A method of treating a viral infection or viral reactivation after latency, the method comprising administering, to a subject in need of such treatment, a compound selected from
- N-((trans)-2-(2-fluorophenyl)cyclopropyl)piperidin-4-amine;
- and
- N-((trans)-2-(o-tolyl)cyclopropyl)piperidin-4-amine;
- or a pharmaceutically acceptable salt thereof.
Dependencies are inferred from the claim text.